Hulio®
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Ankylosing spondylitis
uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis
DATE:
17/09/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
adalimumab
INDICATION:
Ankylosing spondylitis
uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis
DATE:
17/09/2018
STATUS:
Authorized